Table 4 Immunohistochemical stains and KIT status of mast cell sarcoma.
From: Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature
|  | Our study (n = 10) | Literature (n = 24) | Combined (n = 34) |
|---|---|---|---|
CD2 | 1/9 | 7/15 | 8/24 (33%) |
CD25 | 4/9 | 11/16 | 15/25 (60%) |
CD117 | 10/10 | 22/22 | 32/32 (100%) |
Mast cell tryptase | 10/10 | 22/22 | 32/32 (100%) |
CD1a | 0/5 | 0/5 | 0/10 (0%) |
CD3 | 0/8 | 0/11 | 0/19 (0%) |
CD4 | 2/5 | 2/3 | 4/8 (50%) |
CD13 | 3/3 | 4/4 | 7/7 (100%) |
CD20 | 0/7 | 0/8 | 0/15 (0%) |
CD30 | 5/8 | 8/16 | 13/24 (54%) |
CD33 | 10/10 | 5/5 | 15/15 (100%) |
CD34 | 0/8 | 0/12 | 0/20 (0%) |
CD43 | 8/8 | 6/6 | 14/14 (100%) |
CD45 | 5/9 | 8/11 | 13/20 (65%) |
CD56 | 2/5 | 1/3 | 3/8 (38%) |
CD68 | 5/9 | 13/13 | 18/22 (82%) |
CD123 | 2/3 | 1/3 | 3/6 (50%) |
CD163 | 0/6 | 0/3 | 0/9 (0%) |
MPO | 0/7 | 0/10 | 0/17 (0%) |
S100 | 0/10 | 0/7 | 0/17 (0%) |
Overall KIT mutations | 2/9 | 6/19 | 8/28 (29%) |
KIT D816V mutation | 0/9 | 2/19 | 2/28 (7%) |
